SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to positive analyst coverage and increasing optimism around its AI cloud scaling potential, with the community discussing price targets and the possibility of a short squeeze. Bullish investors believe IREN is undervalued and poised for significant growth, while others express concern about its valuation and potential pullback. Discussions also involve comparisons to peers like CIFR and NBIS, and speculation about future deals and market dynamics.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies is trending due to recent case studies showcasing the effectiveness of its CyPath Lung test in early lung cancer detection, potentially reducing the need for invasive procedures. The community is actively discussing the company's fresh story and the potential for a significant upside given its low float. Some traders are setting high price targets while others are cautious about possible dilution.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a recent multi-billion dollar AI compute deal, with community members actively discussing the financial backing from Google and the potential impact on shareholder value. Despite positive news, the stock experienced a sell-off, leading to debates around market manipulation, dilution concerns, and future price targets. Some investors view the dip as a buying opportunity, citing the company's strategic shift towards high-performance computing and long-term growth potential in the AI sector.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members discuss potential catalysts related to reshoring chip manufacturing and government support, possibly including mandates. Optimism is fueled by reported interest from major tech players and significant investment, with some speculating about a potential return to previous highs and beyond. Community members are actively debating the sustainability of the rally and the impact of government policies.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as anticipation builds for a major announcement expected on Monday, sparking community speculation about a potential "Model T moment" related to EVs. The community is actively discussing the potential impact of this announcement, with some expressing skepticism given the company's history and others suggesting partnerships or product innovations may be unveiled. Broader market factors, such as tariffs and potential impact on EVs, are also part of the conversation.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors discuss its potential to break through the $54.50 resistance level, with some citing bullish call flow and projecting a climb to $60 or higher by the end of the year. Community members are actively monitoring volume and chart patterns, while also referencing articles that support a positive outlook for the stock and its sector. Some traders believe the recent acquisition of Alani Nu and overall growth will drive the price up significantly before the next earnings report.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to potential government funding shifts and their impact on the company's strategic rare-earth supply program, a key national security priority. The community is debating the validity of rumors about Congress pulling funding and analyzing the potential for both short-term volatility and long-term growth catalysts. Bullish sentiment remains, fueled by the company's national security status and potential for increased magnet demand.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak ($KODK) is trending amid community discussion around its pharmaceutical manufacturing capabilities and potential benefits from new pharmaceutical tariffs.  Some investors are optimistic about a short squeeze due to high short interest, while others express skepticism based on past performance. The community is actively monitoring for news related to government contracts and the finalization of pension assets.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending as community members discuss the potential for a breakout, buoyed by a Morgan Stanley buy rating and target price. Traders are weighing the possibility of a short squeeze amid observations of steady price levels and biotech sector momentum. Attention is also focused on the company's recent FDA approval and upcoming availability of Palsonify, with some analysts raising price targets significantly.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending amid mixed reactions to its Q4 earnings, which beat EPS estimates but slightly missed revenue expectations. While some investors express concerns about the company's valuation, tariffs, and competition from Amazon, others highlight its strong membership model and consistent earnings. The community is actively debating whether to buy the dip, with opinions split between those seeing long-term upside and those anticipating a correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Shares of Ocugen, Inc. (OCGN) rose 3% on Friday morning after the company reported a better-than-feared first-quarter (Q1) loss.The biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-first-quarter-2025-financial">reported</a> a revenue of $1.5 million, up from $1 million in the corresponding quarter of 2024.Loss per share came in at $0.05, unchanged from the corresponding quarter of 2024, and better than the estimated loss of $0.06 per share.The company, which is developing gene therapies for blindness diseases, ended the quarter with cash and restricted cash totaling $38.1 million, compared to $58.8 million as of Dec. 31, 2024. It expects this will provide runway into the first quarter of 2026.CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the U.S. Food and Drug Administration (FDA) requesting approval for the distribution of three of its products in the next three years.“We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vision," he said.On Stocktwits, retail sentiment around Ocugen jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at high levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_9_57_35_AM_png_0d026d6926.webp" alt="Screenshot 2025-05-09 at 9.57.35 AM.png" width="630" height="63"><figcaption>OCGN's Sentiment Meter and Message Volume as of 9:24 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for the stock, citing the three upcoming FDA applications.<stembedurl>https://stocktwits.com/FannyChmelar/message/614075330</stembedurl>Another noted that the low cash reserve is expected in a company not selling products yet.<stembedurl>https://stocktwits.com/Slapshot22/message/614070848</stembedurl><a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is down by 21% this year and 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-faces-moltiply-lawsuit/chiWtc6RblO">Google Faces $3.3B Lawsuit From Italy’s Moltiply Group: Search Giant Disagrees With ‘Exorbitant’ Private Damages Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.

Equity

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.


Ocugen, Inc.'s stock dropped 2.8% during Wednesday's session but bounced back in extended trading after the company posted a quarterly earnings report that exceeded revenue expectations.The biopharmaceutical company, which focuses on developing gene therapies for eye diseases, reported a fourth-quarter loss of $0.05 per share, in line with estimates.&nbsp;Revenue was $764,000, down from $1.4 million a year ago due to reduced co-development services, but still well above the $400,000 analysts expected.Ocugen's modifier gene therapy platform includes OCU400, OCU410, and OCU410ST, which target inherited retinal diseases (IRDs) and conditions like dry age-related macular degeneration (dAMD) and Stargardt disease.Its OCU400 is in Phase 3 clinical trials for retinitis pigmentosa (RP) in the U.S. and Canada, with enrollment expected to be completed in the first half of 2025.OCU500, Ocugen's inhaled mucosal COVID-19 vaccine, recently received FDA clearance for an Investigational New Drug (IND) application.&nbsp;The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor a Phase 1 trial evaluating two delivery routes — lung inhalation and nasal spray.To extend its cash runway into the first quarter of 2026 and support ongoing clinical trials, Ocugen secured $65 million in equity and debt financing in the second half of 2024.&nbsp;In May, the company was included in the Russell Index.On Stocktwits, sentiment for Ocugen ended Wednesday higher within the 'bullish' zone, with message volume surging 32%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCGN_sentiment_and_message_volume_as_of_March_5_42ff8160da.png" alt="OCGN sentiment and message volume as of March 5.png" width="1316" height="302"><figcaption>OCGN sentiment and message volume as of March 5 | source: Stocktwits</figcaption></figure>One retail trader said the value of Ocugen's pipeline "is insane and I'll be holding when it comes to fruition."<stembedurl>https://stocktwits.com/SGimvesting/message/606846472</stembedurl>Another was hopeful after pointing out that CEO Shankar Musunuri confirmed NIAID's funding support for OCU500's Phase 1 trial next quarter.<stembedurl>https://stocktwits.com/Hamiltoes/message/606856276</stembedurl>Ocugen's ambitious roadmap targets three potential Biologics License Applications (BLAs) between 2026 and 2028, covering RP, Stargardt, and geographic atrophy (GA).However, Ocugen faces a significant short interest rate of 20.7%, according to Koyfin data.&nbsp;The stock trades 1,033% below the average analyst price target of $6.50, with two analysts rating it a 'buy' and two a 'strong buy.'Shares of Ocugen are down over 33% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Ocugen, Inc. (NASDAQ: OCGN) on behalf of the companys shareholders. Since July 2024, shares of Ocugens stock have declined in value from a trading...

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible...

Peering Into Ocugen's Recent Short Interest

OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm OCGN

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the Class Period...

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) for violations of 10(b) and...

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

OCGN
Ocugen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OCGN News

OCGN Ocugen Inc